NCT06914921View on ClinicalTrials.gov

Enteric-Coated Peppermint Oil Versus Standard Antispasmodic in SLC6A4 (5-HTTLPR) Carriers With Irritable Bowel Syndrome.

NACompletedINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

February 4, 2024

Primary Completion Date

January 17, 2025

Study Completion Date

February 1, 2025

Conditions
Irritable Bowel Syndrome (IBS)
Interventions
DIETARY_SUPPLEMENT

Peppermint Oil

"Enteric-coated peppermint oil capsules (\~180 mg total peppermint oil/ capsule) to ensure release in the small intestine.~1 capsule three times daily, 30 minutes before meals, for 12 weeks."

DRUG

A standard antispasmodic

A standard antispasmodic (e.g., mebeverine 135 mg). 1 tablet three times daily, before meals, for 12 weeks.

Trial Locations (1)

630090

Center for New Medical Technologirs, Novosibirsk

All Listed Sponsors
collaborator

Center for New Medical Technologies, Novosibirsk, Russia

OTHER

lead

S.LAB (SOLOWAYS)

OTHER

NCT06914921 - Enteric-Coated Peppermint Oil Versus Standard Antispasmodic in SLC6A4 (5-HTTLPR) Carriers With Irritable Bowel Syndrome. | Biotech Hunter | Biotech Hunter